Navigation Links
Clinical advances
Date:4/16/2010

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus (HBV) and progression to cancers other than hepatocellular carcinoma.

The study found that a higher risk of Non-Hodgkin Lymphoma (NHL) and Cholangiocarcinoma was associated with HBV infection in the presence of higher levels of viral replication.

The data could indicate a causal effect for HBV infection and if proven to be the case in further trials, the benefits of a vaccine against and treatment of HBV will extend beyond reduction in hepatocellular carcinoma.

Worldwide, more than 350 million people are persistently infected with HBV and chronic HBV causes about 1 million deaths each year.

NHL is any of a large group of cancers of the lymphoid system (white blood cells) that can occur at any age. About 80% of all lymphomas diagnosed are NHL and NHL account for 4% of all cancers in the UK.

Cholangiocarcinoma is a cancer of the bile duct cells with no medical treatment except surgery. It is relatively rare with an annual incidence of 1𔃀 cases per 100,000 in the Western world, although rates are increasing.


'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
4. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
5. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
6. Study of African traditional medicine will begin world-first clinical trial
7. New clinical data shows chromium picolinate improves cognitive function
8. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
9. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
10. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
11. NHLBI issues first US von Willebrand Disease clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... of advanced software solutions for pharmaceutical research and development (R&D), today announced ... in omic data analysis and interpretation for the rapidly evolving field of ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
Breaking Biology Technology: